IP Verse

Astellas Pharma competitive analysis

Loading summary...

Latest patents of Astellas Pharma opposed by its competitors

Explore Astellas Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
EP3725778
Aug 18, 2021Formulations Of Enzalutamide12
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical Composition7
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion Product2
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical Composition4

Latest publications and patents of Astellas Pharma New

Explore the latest publications and patents granted to Astellas Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Astellas Pharma

EP3791896
Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerRevoked
EP3318259
Jan 11, 2023Stable Pharmaceutical Composition For Oral AdministrationRevoked
EP3725810
Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerRevoked
EP3725778
Aug 18, 2021Formulations Of EnzalutamideGranted And Under Opposition
EP2345410
Dec 30, 2020Controlled Release Pharmaceutical CompositionGranted And Under Opposition
EP3254695
Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerRevoked
EP2824181
Nov 14, 2018Novel Fgfr3 Fusion ProductRevoked
EP2554168
Jan 24, 2018Controlled Release Pharmaceutical CompositionRevoked
EP2125897
Jan 17, 2018Monoclonal Antibodies For Treatment Of CancerNo Opposition Filed Within Time Limit
EP2743348
Jan 10, 2018Novel Anti-Human Ngf AntibodyNo Opposition Filed Within Time Limit

Latest PTAB cases involving Astellas Pharma

Discover the latest PTAB cases involving Astellas Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Astellas Pharma

IPR2018-00079Oct 16, 2017SAWAI PHARMACEUTICALASTELLAS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Astellas Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ASTELLAS PHARMA - 33 - 1
HAMM & WITTKOPP112 - - -
MAIWALD136 - - -
SANDOZ1181619 -